Highlighting the findings of a recent supply chain report, EPR’s Hannah Balfour discusses measures pharmaceutical suppliers may adopt to establish demand- and crisis-resistant supply chains. Commenting on the findings, Ernst & Young Global Limited colleagues Famke Krumbmüller, Derron Stark and Olaf Zweig elaborate on the impact and lessons learned through the COVID-19 pandemic.
We have reported several times on supply chain resilience since the start of the COVID-19 pandemic,1-3 as the world experienced unprecedented lockdowns and supply disruptions, with interruptions to manufacturing as well as both air transportation and shipping routes. Since the developed regions of the world started to get COVID-19 under control, focus on this matter has only grown – particularly in the pharmaceutical sector, which played a critical role in curbing the devastation caused by the pandemic. But how will this drive for resilience shape the future of pharmaceutical supply chains?
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Promoting supply chain localisation
Famke Krumbmüller, Ernst & Young Global Limited (EY) EMEIA Leader, Geostrategic Business Group, explained that a critical outcome of the pandemic for the sector is that “from the political or regulatory point of view, through COVID-19 the pharma industry and its supply chains became what we would call a ‘strategic sector’, joining more traditional examples such as the technology and defence sectors.” The pandemic attracted the attention of regulators and policy makers to the critical strategic importance of pharma supply chains and “now that this attention has come, we expect more and more government intervention in pharmaceutical supply chains going forwards,” she added.
The shortages experienced by various industries during the pandemic highlighted our dependency on certain areas of the world for supply – for pharma, this was emphasised when logistical challenges in India and China, as well as export restrictions, caused problems in the active pharmaceutical ingredient (API) and generics supply systems. According to Krumbmüller, underpinned by the challenges of COVID-19 and rising geopolitical tensions, a trend has emerged towards reducing dependence on others and thus “the direction the world is heading over the next five to 10 years is more regionalisation”.
But how suitable is localisation for the pharmaceutical industry’s vast and complex supply chains?
Globalised thinking: establishing a hybrid model
“I think one of the challenges is that though regulatory and governmental bodies think localisation will make the difference, and several initiatives have been announced to drive this, pharmaceuticals have very complex supply chains,” commented Olaf Zweig, EY Partner, Life Sciences.
According to a report recently published by EY,4 localisation could take a wide variety of forms, ranging from simply ensuring local stockpiles of finished goods, to the far more ambitious prospect of bringing a whole end-to-end manufacturing process into a single region or nation.
The required investment to localise would also vary significantly depending on which steps of manufacturing are concerned, wrote the authors. “For example, a pharma company could, relatively easily, localise secondary packaging… [However] if companies seek to localise the earlier stages of the manufacturing process… the complexity would rise correspondingly, with increased needs for complex raw materials, skilled labour and higher capital outlay to build sites for higher-technology manufacturing,” wrote the authors.4 The researchers suggest that localising API manufacturing would be the most challenging, given the high levels of investment and technical competency required.
The report also remarked that, in practice, the implications of localisation need to be considered relative to other strategies for enhancing supply chain resilience, noting that pharma companies are already adopting alternative strategies such as multi-sourcing and leveraging local contract development and manufacturing organisations (CDMOs) to enhance their supply chains.4
Moreover, Derron Stark, EY Principal, Strategy and Transactions, revealed that depending on the type of product – small molecule versus biologic – the ability to localise supply and thus the overall supply chain strategy differs. “Small molecules, and APIs in particular, are viewed as commodity technologies and are more likely to be centralised and less likely to be moved from their current supply source to a secondary or localised supply source. Whereas biologics, and we studied allogeneic technologies, are more likely to use localisation as a strategy to improve resilience,” explained Stark.
from the political or regulatory point of view, through COVID-19 the pharma industry and its supply chains became what we would call a ‘strategic sector’, joining more traditional examples such as the technology and defence sectors”
The report revealed that while the industry may move towards localisation to some extent, “ultimately, some combination of localisation and other strategies may provide the most satisfactory answer for all stakeholders”.4
The authors describe the “hub and spoke model” as a potential solution to balance both globalised and localised operations. Within such a system, the manufacturing of a product – either end-to-end or in part – can be localised; while a full-scale manufacturing site acts as a global hub, smaller-scale supply chain operations can be executed locally at spokes.4
According to EY, the hub and spoke system is a cost-efficient model for localising manufacturing; it both increases supply chain agility while negating the need to spend on a full-scale local site. Keeping the equipment in the spoke sites to a minimum can also reduce cost. Fundamentally, they write, it offers “the benefits of localisation strategies while mitigating some of the risks and costs of these strategies”.4
Alternative supply strategies
The collaborative key
Outsourcing activities to local contract development and manufacturing organisations (CDMOs) is just one collaborative solution to localising aspects of supply. Within the hub and spoke model, the report offers several, perhaps more controversial, collaborative options that could deliver the desired supply chain flexibility while mitigating the risks for organisations.
Such solutions include the opportunity for joint warehousing, where companies share warehousing capacity for raw materials and consumables; not only does this provide a localised source, but the co-location of supplies would enable easier sharing of materials between companies where necessary in the face of disruptions.4 Moreover, sharing large-scale manufacturing facilities would enable companies to reduce their expenditure and risk while increasing agility by allowing access to a full-scale local site.
Supply chain visibility, regulatory adjustment and more
It is important to note that while some industries stalled in the face of COVID-19, the innovative pharmaceutical sector was reasonably resilient, experiencing minimal supply shortages, according to Stark. “This industry’s service levels stayed at pre-pandemic levels and, in some cases, actually improved because of the increased focus and application of more resources and manpower to ensure that products got to market,” he highlighted.
However, Stark noted that the pandemic emphasised certain weaknesses within the industry, such as in its supply chain visibility and subsequent ability to cope with large fluctuations in demand. “As a result, supply chain visibility, digitalisation and automation have risen to the top of innovative pharma’s agenda. They were on the agenda prior to the pandemic for decades, but companies have doubled down on their investments to accelerate getting connectivity and visibility to their raw material and component suppliers, as well as to customers, to be able to see and respond to their demand signals better, and to have some capability with demand sensing.”
The report asserts that improving end-to-end supply chain visibility through the development of integrated digital platforms would enable data from manufacturers, suppliers and wholesalers to be linked, providing insight into the real-time supply chain situation and enabling more efficient management and intervention.4
The authors also suggest two potential regulatory adjustments that could enhance resilience. They describe an operating model that could expedite changes to manufacturing and supply for “companies recognised as trusted and competent”.4 Under the “regulatory notification principle”, such companies would be considered compliant as soon as they provide the necessary change notification information to regulators, allowing organisations to implement changes while they work to supply full change documentation and stability data later. Essentially, trusted companies would be able to make changes without the need for a pre-approval inspection or data review and approval, thereby increasing agility and reducing potential downtimes.4
Small molecules, and APIs in particular, are viewed as commodity technologies and are more likely to be centralised… Whereas biologics, and we studied allogeneic technologies, are more likely to use localisation as a strategy to improve resilience”
They also suggest that by making regulatory filings supplier agnostic, substitute sources could be more easily utilised.4 Stark explained that many companies are already multi-sourcing both raw materials, components, etc, and sites for API production and formulation. Qualifying secondary sources, he noted, will be “one of the most impactful measures, and one that companies have already started to take,” adding that “many companies identified that cross registration of facilities, where finished product sites are not just registered to service one region or market, was a critical component to their ability to supply during the pandemic.”
“These are just two examples of how this collaboration between the regulatory bodies and the pharmaceutical industry can be used to increase resilience and build future supply chains that are even more agile,” stated Zweig.
The authors acknowledge that the potential implications of each of the alternative approaches are wide-ranging and challenging to predict; however, they assert that, in comparison to end-to-end localisation, such methods “require comparatively low investment to realise”.
Future thinking
Zweig noted that, since every company operates differently, there is likely not a single model or strategy to act as a “silver bullet” for all companies. He also explained that, though not emphasised in the report, a critical component of supply chain resilience is reimbursement for the investment made: “If you take all these measures in order to run with very high resilience, then it also needs to be considered that this requires a proper reimbursement.”
Stark highlighted that everything comes down to collaboration, with Krumbmüller adding: “it is critical to ensure that collaboration exists to make sure the regulators can be given a “reality check” on their proposals; since they are often not necessarily married to the pathway, but instead focused on the outcomes, collaboration is extremely important to ensure the results are delivered in the most realistic and efficient way possible.”
Olaf Zweig, EY Partner, Life Sciences
Derron Stark, EY Principal, Strategy and Transactions
Famke Krumbmüller, EY EMEIA Leader, Geostrategic Business Group
About the author
Hannah Balfour is the Science Writer for European Pharmaceutical Review.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.